| Acute myeloid leukemia: a classification and treatment update. | |
| | |
MedLine Citation:
|
PMID: 14603550 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Approximately 11,000 Americans will be diagnosed with acute myeloid leukemia (AML) in 2003, and about 75% ultimately will die from the disease. Despite significant advances in understanding biologic, molecular, and cytogenetic aspects of this malignancy, several other areas remain poorly understood. During the 1990s, significant advances in the characterization of this condition have shown that AML affects elderly patients more frequently. Treatment of patients in this age group poses a greater challenge partly because of increased tumor resistance and the presence of multiple medical comorbidities that may contraindicate therapy. New therapeutic approaches are promising and have renewed enthusiasm and optimism among patients and healthcare providers. Future treatment strategies for patients with AML most likely will include combinations of biologic agents with defined molecular targets (e.g., monoclonal antibodies, retinoids, hypomethylating agents, tyrosine kinase inhibitors). |
| | |
Authors:
|
Christine Scura Iovino; Luis H Camacho |
Publication Detail:
|
Type: Case Reports; Journal Article; Review |
Journal Detail:
|
Title: Clinical journal of oncology nursing Volume: 7 ISSN: 1092-1095 ISO Abbreviation: Clin J Oncol Nurs Publication Date: 2003 Sep-Oct |
Date Detail:
|
Created Date: 2003-11-07 Completed Date: 2003-12-10 Revised Date: 2009-11-19 |
Medline Journal Info:
|
Nlm Unique ID: 9705336 Medline TA: Clin J Oncol Nurs Country: United States |
Other Details:
|
Languages: eng Pagination: 535-40 Citation Subset: N |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Age Factors Antibodies, Monoclonal / therapeutic use Antineoplastic Combined Chemotherapy Protocols / therapeutic use Drug Resistance, Neoplasm Hematopoietic Stem Cell Transplantation Humans Immunotherapy Leukemia, Myeloid, Acute / classification*, epidemiology, therapy* Male Patient Selection Prognosis Protein-Tyrosine Kinases / antagonists & inhibitors Remission Induction / methods Retinoids / therapeutic use Salvage Therapy Severity of Illness Index |
| Chemical | |
Reg. No./Substance:
|
0/Antibodies, Monoclonal; 0/Retinoids; EC 2.7.10.1/Protein-Tyrosine Kinases |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Facilitating exercise adherence for patients with multiple myeloma.
Next Document: Diffuse malignant pleural mesothelioma: Part II. Symptom management.